

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**EVERGRANDE HEALTH  
INDUSTRY GROUP**

**EVERGRANDE HEALTH INDUSTRY GROUP LIMITED**

**恒大健康產業集團有限公司**

*(a company incorporated in Hong Kong with limited liability)*

**(Stock code: 708)**

**MAJOR TRANSACTION**

**BID-WINNING OF THE LAND USE RIGHTS OF 11 LAND PLOTS IN XINGYANG,  
ZHENGZHOU CITY, HENAN PROVINCE**

Evergrande Health Industry Group Limited is pleased to announce that, on 7 September 2017, it has, via its subsidiary, won the bid for the state-owned construction land use rights of 11 land plots in Xinyang, Zhengzhou City, Henan Province, China at a total consideration of RMB1,829,900,000.

In accordance with the Listing Rules, as the highest applicable percentage ratio in respect of the Xinyang Land Acquisition is more than 25% but less than 100%, the Xinyang Land Acquisition constitutes a major transaction of the Company and is subject to announcement and Shareholders' approval requirements under the Listing Rules.

The transaction has been approved in writing by the controlling shareholder of the Company. A circular will be despatched to the Shareholders by the Company as soon as practicable in accordance with the Listing Rules setting out (among others) further details of the Xinyang Land Acquisition. The Company will apply to the Stock Exchange for a waiver under Rule 14.41(a) of the Listing Rules, to despatch the circular on or before 31 October 2017, so as to allow sufficient time for the preparation of the relevant information for inclusion in the circular.

Evergrande Health Industry Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that, on 7 September 2017, the Company has, via its subsidiary (the “**Bid Winner**”), won the bid for the state-owned construction land use rights of land plots No. Xing Zheng Chu (2017) 9–7 (land for commercial use), No. Xing Zheng Chu (2017) 12–3 (land for residence use), No. Xing Zheng Chu (2017) 13–2 (land for residence use), No. Xing Zheng Chu (2017) 14–2 (land for residence use), No. Xing Zheng Chu (2017) 15 (land for residence use), No. Xing Zheng Chu (2017) 16–3 (land for commercial use), No. Xing Zheng Chu (2017) 45–1 (land for commercial use), No. Xing Zheng Chu (2017) 47–4 (land for residence use), No. Xing Zheng Chu (2017) 48–1 (land for residence use), No. Xing Zheng Chu (2017) 50–1 (land for residence use) and No. Xing Zheng Chu (2017) 52–1 (land for commercial use) in Xingyang, Zhengzhou City, Henan Province, China (the “**Land Plots**”) (the “**Bid**”). The Land Plots have a total area of 438,289.55 square meters, and a total aboveground construction area of approximately 965,392.82 square meters, with terms of 70 years and 40 years for the land use rights for residence use and commercial use, respectively. On 8 September 2017, the Bid Winner will enter into a total of 11 relevant land use rights bid confirmations with the Ministry of Land and Resources of Xingyang (the “**Vendor**”), the vendor of the use rights of the Land Plots, in relation to the acquisition of the use rights of the Land Plots (the “**Xingyang Land Acquisition**”).

## **CONSIDERATION FOR THE XINGYANG LAND ACQUISITION**

Consideration: RMB1,829,900,000 (to be settled by the Group by internal resources)

The consideration for the Xingyang Land Acquisition was determined by way of public listing and tendering. The consideration will be fully paid to the Vendor on 8 September 2017 when the Bid Winner has entered into relevant land use rights bid confirmations with the Vendor.

The Bid Winner will also enter into the assignment agreement for state-owned construction land use rights (《國有建設用地使用權出讓合同》) in respect of the Xingyang Land Acquisition with the Vendor.

## **INFORMATION ABOUT THE “ZHENGZHOU EVERGRANDE INTERNATIONAL HEALTH CITY” IN ZHENGZHOU XINGYANG HEALTH PARK, XINGYANG, ZHENGZHOU CITY, HENAN PROVINCE, CHINA**

Zhengzhou Xingyang Health Park, with total area of 117 square kilometers, forms a part of the western new city in Zhengzhou urban area. It aims to create different functional segments covering medical healthcare, technology education and development, leisure service and elderly care, as well as eco-friendly residential area, and strives to be established as a medical and healthcare center in the Central China, and even across the whole China.

## **REASONS AND BENEFITS OF THE TRANSACTION**

The Group focuses on community health management and elderly care services at homes. Through the cooperation with Brigham and Women’s Hospital (the main teaching hospital of Harvard Medical School) and other institutions, the Group has established an international medical group offering the

latest early prevention, precise treatment and continuous rehabilitation programmes for cancers. The Group, together with international leading medical cosmetology and anti-aging institutions, jointly offer the latest medical cosmetology and anti-aging services in Asia, thus providing comprehensive scientific healthcare services covering the whole treatment cycle for families across China. Zhengzhou Evergrande International Health City adheres to create health-orientated homes while developing itself into a demonstrative health city, eco-friendly city and liveable city in Central China, even across the whole China.

The Land Plots will be used for the construction of the health experience center, the five-star healthcare hotel and the headquarters for domestic and overseas large-to-medium scale medical enterprises. Meanwhile, adhering to the brand new “1+N” concept (family+elderly care, healthcare, medical, anti-aging, medical cosmetology, leisure and cultural activities, sports, family activities and diversified life etc.) and the healthy lifestyle covering the whole life cycle in combination of prevention, treatment and healthcare, and through the installation of relevant ancillary facilities for elderly care, entertainment, sports and family activities, the Land Plots will be developed into a demonstrative all-age health community in Central China, and even across the whole China.

On the basis of the above reasons and benefits, the directors of the Company believe that the terms of the Bid, the Xingyang Land Acquisition and the transactions contemplated thereunder are fair and reasonable and in the interests of the Company and its Shareholders as a whole.

## **INFORMATION ABOUT THE GROUP**

The principal business activities of the Group are “Internet+” community healthcare management, high-end international hospitals, elderly care industry, medical cosmetology, anti-aging management as well as the sales of travel, dining and lifestyle magazines and contents.

## **INFORMATION ABOUT THE VENDOR**

The Vendor is a government department in Xingyang, China and an authority under Zhengzhou Municipal Government.

To the best of knowledge, information and belief of the directors of the Company, after having made all reasonable enquiries, Xingyang government (being the authority which the Vendor is subordinated to) is a government institution, and Xingyang government and its ultimate beneficial owner(s) are third parties independent of the Company and its connected persons and are not the connected persons of the Company.

## **LISTING RULES IMPLICATIONS**

In accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”), as the highest applicable percentage ratio in respect of the Xingyang Land Acquisition is more than 25% but less than 100%, the Xingyang Land Acquisition constitutes a major transaction of the Company and is subject to announcement and Shareholders’ approval requirements under the Listing Rules.

In accordance with the Listing Rules, a major transaction is subject to Shareholders' approval. To the best of the knowledge, information and belief of the directors of the Company, after having made all reasonable enquiries, as no shareholder of the Company ("**Shareholder**") has material interests in the transaction, no Shareholder would be required to abstain from voting if the Company were to convene a general meeting for approving the transaction. The Company will not be required to convene a general meeting for approving the transaction as the Company has obtained written Shareholder's approval from Evergrande Health Industry Holdings Limited, the controlling shareholder of the Company (the "**Controlling Shareholder**"), in lieu of convening a general meeting as permitted by Rule 14.44 of the Listing Rules. The Controlling Shareholder directly holds 6,479,500,000 shares in the Company, representing approximately 74.99% of the issued shares of the Company as at the date of this announcement.

## **GENERAL**

A circular will be despatched to the Shareholders by the Company as soon as practicable in accordance with the Listing Rules setting out (among others) further details of the Xingyang Land Acquisition. The Company will apply to the Stock Exchange for a waiver under Rule 14.41(a) of the Listing Rules, to despatch the circular on or before 31 October 2017, so as to allow sufficient time for the preparation of the relevant information for inclusion in the circular.

**There can be no assurance that any forward-looking statements regarding the business development of the Group set out in this announcement and any of the matters set out herein are attainable, will actually occur or will be realised or are complete or accurate. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the securities of the Company and not to place any excessive reliance on the information disclosed herein. Any Shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.**

By Order of the Board  
**Evergrande Health Industry Group Limited**  
**Tan Chaohui**  
*Chairlady*

Hong Kong, 7 September 2017

*As at the date of this announcement, the executive directors of the Company are Ms. Tan Chaohui and Mr. Han Xiaoran; and the independent non-executive directors of the Company are Mr. Chau Shing Yim David, Mr. Guo Jianwen and Mr. Xie Wu.*